Once upon a time, Australia made a quiet but consequential promise to its innovators. It said: take a risk, do the hard science, spend years chasing a breakthrough that might not come, and we’ll back you.
That promise had a name called “R&D Tax Incentive” or “R&DTI”. For over a decade, it worked as advertised. A broad, industry-agnostic entitlement that asked only one thing: are you genuinely pushing the boundaries of knowledge? If yes, you are in.
Then came the “Ambitious Australia” report, released on 17 March 2026, and the promise started to change shape.
One Day, the Goalposts Moved
The Denholm panel’s recommendations did not just tinker with the Research and Development Tax Incentives. They introduced a new condition that redefines what the government considers a worthy recipient of public support.
For SMEs seeking refundable R&DTI benefits, ongoing access will now hinge on hitting a mandatory revenue growth target of 5% above the Consumer Price Index, sustained over three years.
Miss that benchmark for two consecutive years, and you are off the program—no more refundable offset for you. Just an “off-ramp” and, as a consolation, a discretionary R&D Collaboration Voucher worth up to $150,000, provided you can find a university partner and navigate yet another layer of administrative process.
This is what the report calls the Growth-Linked Access rule. And on the surface, it sounds reasonable. Shouldn’t taxpayer support go to companies that are actually growing? Shouldn’t there be some accountability?
You might be wondering the same thing. Let’s dig into why this logic falls apart the moment you apply it to how real innovation actually works.
The Fundamental Misread of What R&D Actually Is
Research and development is not a sales strategy. It is not a marketing channel. It is not a revenue lever you pull on a quarterly timeline. True R&D is, by its nature, uncertain, non-linear, and often commercially silent for extended periods.
Think about penicillin. Alexander Fleming’s discovery sat largely dormant for over a decade before Howard Florey and Ernst Chain developed it into a usable medicine. The gap between the scientific moment and the commercial one was fifteen years. Under a Growth-Linked Access rule applied to the 1930s, Fleming’s lab doesn’t make the cut.
Consider mRNA technology. Katalin Kariko spent decades at the University of Pennsylvania facing grant rejections and institutional scepticism. Her work didn’t scale commercially in any recognisable sense for most of her career. It became a global lifesaver in 2020. A revenue growth mandate would have written her off as a bad investment years earlier.
These are not edge cases. They are the rule. Deep tech, biotech, quantum computing, and advanced materials science. These fields operate on timelines that do not fit neatly into a 3-year revenue window. According to research published by the OECD, the average time from R&D expenditure to commercial output in pharmaceutical development exceeds 12 years or more. 12 years! The Growth-Linked Access rule does not accommodate that reality. It punishes it.
The Government Is Picking Winners, and It Is Choosing the Wrong Ones
Here is the uncomfortable truth buried inside this policy: the Growth-Linked Access rule of government doesn’t treat all innovators equally. It systematically advantages the companies that commercialise quickly. Those involved in software businesses, SaaS platforms, and fast-moving consumer tech, over those that operate in long-cycle, capital-intensive research.
A software startup iterating on a B2B product can hit 5% above CPI growth within 3 years. A biotech company running clinical trials cannot. A deep tech firm developing a revolutionary battery chemistry cannot. A university spinout working on novel alloys for aerospace cannot.
What the government is doing, perhaps unintentionally, is engineering a two-tier innovation system: one where fast-to-market businesses thrive under the R&DTI, and another where “slow-and-steady” innovators, who are the ones taking the biggest scientific risks, are quietly pushed out.
That is not a neutral policy outcome. That’s a choice. And it is a choice with real consequences for Australia’s capacity to generate sovereign capability in areas like defence technology, medical research, and clean energy.
Because of That, the R&DTI Becomes Something Else Entirely
The R&DTI was built on a specific philosophical premise: that markets systematically underfund R&D because the benefits of innovation often spill over to competitors and society at large, creating a gap between private and social returns. The tax incentive exists to correct that market failure.
The Growth-Linked Access rule abandons that premise entirely. By tying eligibility to revenue performance, the policy now rewards businesses that are already succeeding commercially. Those are precisely the businesses that markets are best at funding on their own, through revenue, through venture capital, through growth equity. They do not need corrective intervention. They are already working.
What this means in practice is that the R&DTI stops being an innovation catalyst and starts being a generic business growth subsidy. That is not a subtle distinction. It represents a complete inversion of the program’s rationale.
And it raises an obvious question: if the government wants to subsidise business growth, why dress it up as an R&D incentive? Why not just call it what it is?
The “Success Tax” Problem Nobody Is Talking About
There is a deeper irony embedded in the Growth-Linked Access rule that deserves more attention than it’s getting.
The report acknowledges, without apparent self-awareness, that some low-growth SMEs may become ineligible under a more focused system. This is presented as a positive aspect and a feature, not a bug, showing that the system is improving in its focus and effectiveness.
But think about what that actually means for the companies involved. A startup that spent years building something technically ambitious, investing in genuine experimental development, relying on the refundable offset to keep operating, now faces a cliff edge. Not because science failed. Not because its claims were ineligible. But because its revenue did not grow fast enough to satisfy a metric designed for a different kind of business.
That’s not a targeted policy. That’s a trap. The government extended the safety net, encouraged companies to build their financial models around it, and then introduced a condition that makes the net disappear at the exact moment many long-cycle R&D companies need it most during the years before commercialisation, when costs are high, and revenue is thin.
For the estimated 30% of current claimants who may not meet these growth targets, the message is stark: your technical risk is no longer considered worth the investment unless it comes packaged with rapid fiscal expansion.
Also read: Australia’s R&D Tax Incentive Is Changing: What the SERD Report Means for Your Business
What Moonshot Projects Actually Need From Government
You might be thinking: surely the Ambitious Australia report offers some protection for genuinely long-cycle innovators? And to be fair, it does make some concessions. Deep tech startups in pharmaceuticals, for instance, can apply for extensions to the Premium Startup Stream every three years, delaying the point at which the Growth-Linked Access rule applies to them. There is also a three-year on-ramp when firms graduate into the SME and Scaleup Stream before the growth mandate kicks in.
But these are band-aids on a structural problem. The on-ramp eventually ends. The extensions require repeated administrative effort. And the underlying logic of the policy that revenue growth is a valid proxy for R&D quality remains unchanged throughout.
What genuine moonshot projects need from the government is the opposite of what this policy provides. They need:
- Patience: Funding that does not expect to achieve commercial success in the next three years.
- Risk tolerance: The acceptance of failure as an inevitable part of R&D (the price of innovation).
- Stability: A predictable support environment that lets researchers plan multi-year programs without worrying about arbitrary eligibility cliffs.
- Outcome neutrality: Indicators to evaluate the performance of the research activity, and not how fast the revenue line is growing.
The Growth-Linked Access rule fails on all four counts. It demands speed, penalises failure, introduces eligibility uncertainty, and measures commercial outcomes rather than research quality.
Finally, We Have to Ask What “Ambitious” Actually Means
The report is called “Ambitious Australia.” It’s a name that invites scrutiny of what ambition means in practice.
Is ambition a biotech company running a decade-long clinical trial on a treatment for a rare disease? Is it a materials science lab spending years on a compound that might one day replace rare earth elements in batteries? Is it a quantum computing team building the architecture that could reshape cryptography and computing power within a generation?
Or is ambition, in the government’s current framing, a SaaS company hitting 8% ARR growth and spending some of that on product development?
The Growth-Linked Access rule answers that question quietly but clearly. It defines ambition as commercial velocity. And in doing so, it narrows the definition of innovation to something small enough to fit inside a revenue spreadsheet.
That’s not ambitious. That’s cautious. It’s the government protecting its investment by only backing companies that already look like they are winning.
What Should Change Before This Becomes Law
The critique here is not that the R&DTI doesn’t need reform. It clearly does! There are legitimate concerns about compliance costs, eligibility boundaries, and whether the program reaches companies with genuine research activity. Those are worth addressing.
What should not change is the fundamental purpose of the R&D Tax Incentive Program, which is to support the risky, uncertain, commercially unproven work that markets won’t fund on their own.
Before the Growth-Linked Access rule is locked in, policymakers should consider:
- Differentiating growth metrics by sector: A biotech company has a very different timeline than a SaaS company; therefore, they are best measured using different criteria.
- Replacing revenue growth with research intensity metrics: Measuring R&D expenditure as a proportion of operating costs, or the novelty of the technical claims, rather than the speed of the revenue line.
- Extending the on-ramp period for demonstrably long-cycle research: Clinical trial programs, fundamental physics, novel material development
- Making the R&D Collaboration Voucher an entitlement rather than a discretionary grant: if you’re pushed off the R&DTI, your fallback shouldn’t depend on someone deciding you deserve it
The Real Stakes Behind a Policy That Sounds Sensible
Australia already faces a $53 billion gap in late-stage venture capital compared to the United States, according to figures cited in the Ambitious Australia report itself. Large-business R&D investment has dropped by 24% over the last decade. The country is already losing researchers and founders to markets that offer better support conditions.
Against that backdrop, introducing a Growth-Linked Access rule that squeezes out the companies most likely to generate genuine scientific breakthroughs isn’t just a policy error. It’s a compounding one.
The companies that leave the R&DTI program because they cannot hit 5% above CPI will not necessarily shut down. Some will relocate. They will take their IP, their talent, their eventual breakthroughs, and move to a jurisdiction that doesn’t ask them to prove commercial success before it agrees to support their research.
And Australia will watch from the outside as the discoveries it once funded deliver returns somewhere else.
The Growth-Linked Access rule, dressed up in the language of ambition and efficiency, risks accelerating exactly the outcome the Ambitious Australia report claims to prevent. That’s worth pausing on well before the recommendations become legislation.
